Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

CNS 2Lymphoid 1

Conditions

Brain Neoplasms 1899Glioblastoma 1791Glioma 1126Central Nervous System Neoplasms 599Astrocytoma 593Neuroblastoma 552Gliosarcoma 465Oligodendroglioma 363Neoplasms 312Breast Neoplasms 273Medulloblastoma 272Carcinoma, Non-Small-Cell Lung 225Recurrence 198Sarcoma 183Neoplasm Metastasis 183Melanoma 181Meningioma 177Ependymoma 174Lung Neoplasms 156Lymphoma 133Osteosarcoma 126Meningeal Carcinomatosis 126Neurofibromatosis 1 114Wilms Tumor 111Ovarian Neoplasms 110Diffuse Intrinsic Pontine Glioma 105Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Rhabdomyosarcoma 100Lymphoma, Non-Hodgkin 96Burkitt Lymphoma 89

Interventions

XENP 1595 1Sodium Chloride 1Saline Solution 1Dexmedetomidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neurocognitive Disorders × CNS × Clear all
NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Inmune Bio, Inc.

Phase 2 Terminated
11 enrolled
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

NCT02810899 2016-09-29

Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy

Peking University First Hospital

Phase 4 Completed
60 enrolled
CNS

Brain Neoplasms, Neurocognitive Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡